

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 00858)

PROFIT ALERT

This announcement is made by Extrawell Pharmaceutical Holdings Limited (the “**Company**“, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2017 (the “**Management Accounts**”), the Group expects to record an increase in profit of about HK\$14 million in the current period, as compared to that of the six months ended 30 September 2016. The Board wishes to point out that such increase is primarily attributable to decrease in loss related to fair value change of the derivative component of the Group’s investments in convertible bonds of approximately HK\$10 million and increase in effective interest income from investments in convertible bonds of about HK\$5 million, which are both non-cash items. In addition, in spite of having improvement in performance of the Group’s manufacturing segment, the Group’s trading segment of imported pharmaceutical products turned into a loss position in the current period, which is attributable to significant decrease in sales due to intensified competition from competing products of local manufacturers in China market and the negative impact arising from increasing regulatory scrutiny on imported products, and such difficult market condition will likely affect the performance of the Group’s trading segment in the second half of the financial year. While the Group will continuously endeavor to improve the Group’s business operations, it will seek potential business opportunities with an aim of diversifying its revenue stream.

The Company is still in the process of preparing the interim results of the Group for the six months ended 30 September 2017, the information as set out above is only based on the preliminary assessment by the Board on the information currently available to it, including the Management Accounts, which have yet to be confirmed. The unaudited consolidated interim results of the Group for the six months ended 30 September 2017 are expected to be announced by the Company before the end of November 2017.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 13 November 2017

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen, Mr. Liu Kwok Wah and Mr. Lu Zhiqiang, and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

* *For identification purpose only*